Adverse events Assessed as: occurrence of one or more major adverse events requiring withdrawal of treatment · people with nerve damage (< 6 months' duration) in leprosy
Corticosteroids showed no clear difference in adverse events Assessed as: occurrence of one or more major adverse… compared with placebo (moderate certainty).
1 finding from 1 review
1Small sample size. · people with nerve damage (< 6 months' duration) in leprosy
1 finding from 1 review
no estimate extracted
1 participants
GRADE not reported
Improvement in sensory nerve function at 1 year · people with nerve damage (6 to 24 months' duration) in leprosy
Corticosteroids showed no clear difference in improvement in sensory nerve function at 1 year compared with placebo (moderate certainty).
1 finding from 1 review
Improvement in motor nerve function at 1 year · people with nerve damage (6 to 24 months' duration) in leprosy
1 finding from 1 review
Death ‐ at 180 days after ICU admission, in total population randomised · critically ill patients
Corticosteroids showed no clear difference in death ‐ death at 180 days in total population randomised compared with placebo compared (high certainty).
1 finding from 1 review
Serious adverse events (dichotomous data) ‐ shock · critically ill patients
Corticosteroids showed no clear difference in serious adverse events (dichotomous data) ‐ shock compared with placebo compared (high certainty).
1 finding from 1 review
Serious adverse events (dichotomous data) ‐ serious infection · critically ill patients
Corticosteroids showed no clear difference in serious adverse events (dichotomous data) ‐ serious infection compared with placebo compared (high certainty).
1 finding from 1 review
Serious adverse events (dichotomous data) ‐ suspected or probable pneumonia · critically ill patients
Corticosteroids showed no clear difference in serious adverse events (dichotomous data) ‐ suspected or probable… compared with placebo compared (high certainty).
1 finding from 1 review
Serious adverse events (continuous data) ‐ blood glucose (mg/dL) on day 7 · critically ill patients
1 finding from 1 review
Occurrence of CIP/CIM ‐ in the total population randomised · critically ill patients
Corticosteroids showed no clear difference in occurrence of CIP/CIM ‐ in total population randomised compared with placebo compared (low certainty).
1 finding from 1 review
Occurrence of CIP/CIM ‐ in screened population · critically ill patients
Corticosteroids showed no clear difference in occurrence of CIP/CIM ‐ in screened population compared with placebo compared (moderate certainty).
1 finding from 1 review
Incomplete recovery at end of study № of participants: 766 (3 RCTs) · Bell's palsy
Antivirals plus corticosteroids showed no clear difference in incomplete recovery at end of study № of participants: 766 (3 RCTs) compared with corticosteroids plus placebo or no treatment (AS versus OS) (low certainty).
1 finding from 1 review
RR 0.81 [0.38, 1.74]
Studies not reported
Low
Motor synkinesis or crocodile tears № of participants: 469 (2 RCTs) · Bell's palsy
Antivirals plus corticosteroids probably leads to lower motor synkinesis or crocodile tears № of participants: 469 (2 RCTs) compared with corticosteroids plus placebo or no treatment (AS versus OS) (moderate certainty).
1 finding from 1 review
RR 0.56 [0.36, 0.87]
Studies not reported
Moderate
Adverse events № of participants: 656 (2 RCTs) · Bell's palsy
It is very uncertain whether antivirals plus corticosteroids changes adverse events № of participants: 656 (2 RCTs) compared with corticosteroids plus placebo or no treatment (AS versus OS) (very low certainty).
1 finding from 1 review
RR 1.17 [0.81, 1.68]
Studies not reported
Very low
Improvement in disability grade after 4 weeks · patients with Guillain‐Barré syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Improvement in disability grade Defined as achievement of a specified degree of improvement · patients with Guillain‐Barré syndrome
It is very uncertain whether tripterygium polyglycoside changes improvement in disability grade Defined as achievement of a… compared with corticosteroids (very low certainty).
1 finding from 1 review
Time from randomisation until recovery of unaided walking · patients with Guillain‐Barré syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Time from randomisation until discontinuation of ventilation (for those ventilated) · patients with Guillain‐Barré syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Death · patients with Guillain‐Barré syndrome
1 finding from 1 review
Death or disability after 12 months · patients with Guillain‐Barré syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found